PR87336

CATANIA, Italy, Dec. 21, 2020 /PRNewswire=KYODO JBN/ --

- Spectacle-free uninterrupted high-quality vision for cataract patients

    SIFI, a leading international eye care company, today announces the launch

of the WELL FUSION(TM) system and the Mini WELL PROXA(R) intraocular lens,

offering a novel solution that provides cataract patients the option to treat

presbyopia with spectacle-free uninterrupted high-quality vision at all

distances and in all lighting conditions.

    SIFI has developed Mini WELL PROXA building upon the outstanding clinical

outcomes of Mini WELL(R) [1-5], SIFI's premium IOL launched in 2016, which

demonstrated a very broad extension of the depth of focus and excellent quality

of vision.

    Mini WELL PROXA is designed to be implanted in the non-dominant eye,

alongside with Mini WELL in the dominant eye, to bridge the near vision gap

typically associated with Extended Depth of Focus IOLs, whilst continuing to

ensure high quality vision at all distances and in all lighting conditions.  

    Mini WELL and Mini WELL PROXA intraocular lenses share the same EDOF

platform based on the distribution of spherical aberrations of opposite sign in

the central part of the optics, a SIFI proprietary and patented technology in

presbyopia-correcting IOLs.

    Mini WELL PROXA is now commercially available in Italy, Romania and Spain;

other European countries will follow throughout 2021.

    Currently, over 1.8 billion people in the world are afflicted with

presbyopia6, meaning difficulty seeing objects at a near distance with

increasing age, typically starting after 40.

    "We are excited to introduce Well Fusion, a first-in-kind technology that

has shown – throughout product and early clinical development – the true

potential to bring together the best of the current gold standards in cataract

refractive surgery, EDOF and Trifocal IOLs." said Fabrizio Chines, SIFI's

Chairman and CEO. "We believe this represent a remarkable step forward in the

quest to offer ophthalmologists and their patients an optimal surgical option

for presbyopia correction."

About SIFI

    SIFI is a leading ophthalmic company, headquartered in Italy, focusing on

eye care since 1935. SIFI develops, manufactures, and markets innovative

therapeutic solutions for patients with ophthalmic conditions. SIFI is fully

committed through its R&D to improve the quality of life of patients, exporting

treatments to more than 20 countries worldwide with a direct presence in Italy,

Spain, France, Romania, Mexico and Turkey.

    Key Contact

    press@sifigroup.com

    References:

    1. Savini G, et al. JRS 2018 Apr;34(4):228-235.

    2. Savini G, et al. Eye 2019 Mar;33(3):404- 410.

    3. Bellucci R, et al. JCRS 2019 July;45(7):919-926.

    4. Pedrotti E, et al. JRS 2020 Apr;36(4):214-222.

    5. Auffarth GU, et al. JRS 2020 July;36(7):426-434

    6.WHO World report on vision (2019) Retrieved from

     https://www.who.int/publications/i/item/world-report-on-vision.

    Logo:https://mma.prnewswire.com/media/1337809/SIFI_Logo.jpg

    Source: SIFI S.p.A.